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The aminoglycoside antibiotics have been a mainstay in the systemic therapy for serious Gram-negative 
infections for nearly five decades. The adverse effects of ototoxicity and nephrotoxicity, first recognized after the 
introduction of streptomycin in the 1940s [l, 21, still pose many unresolved basic questions and continue to 
complicate the clinical application of these drugs. It has been well-documented that aminoglycoside-induct 
hearing loss is related to the progressive and irreversible destruction of cochlear outer hair cells from the inner ear 
[3]. A variety of biochemical effects have been described and mechanisms of toxicity advanced 141, but no 
cellular event has yet been causally linked to cytotoxicity or cell death. 
In contrast to their well-documented toxicity in vivo, aminoglycosides have no acute toxicity to either 
cochlear or renal cells in vitro [5, 61. This discrepancy between in vivo and in vitro effects suggests that a 
metabolic event is required for the toxic actions of these antibiotics. The possibility of aminoglycoside-delved 
toxic metabolites has seldom been considered, and direct experimental evidence for such metabolites has been 
lacking [7, 81. Indeed, it has remained dogma that these drugs do not undergo significant metabolism prior to 
their renal elimination [9]. 
In this study, we used isolated cochlear outer hair cells in a recently developed cytotoxieity assay (5, lo] 
to test the toxicity of aminoglycosides after incubation with drug-metabolizing hepatic enzymes. The subcellular 
S9 fraction employed (9000 g supernatant from phenobarbital-treated animals) has been well-established for 
xenobiotic metabolism in the Ames test [ll]. Gentami~in incubated with the hepatic enzymes decreased the 
viability of the cells, while the untreated parent antibiotic had no cytotoxic effect; evidence for the involvement of 
oxidative metabolism in the formation of the toxic metabolite is provided. These results should lead to new 
rational approaches to the mechanism and prevention of aminoglycoside-induced toxicity. 
METHODS 
Liver homogenates (3 mL of 0.15 M KCl/g liver, dispersed with a Brinkmann Polytron for 10 set) from 
guinea pigs treated with phenob~bital (0.1% in inking water for 10 days) were centrifuged at 9000 g for 10 min 
and the supematants (S9) stored at -80° in glass vials. The S9 fraction was combined for each experiment with 
100 mM sodium phosphate buffer (pH 7.40), 4 mM NADP, 5 mM glucose-6-phosphate, 30 mM KC1 and 7 mM 
MgCl2 [ 111, and 10 mM gentamicin sulfate (Sigma, St. Louis, MO) was incubated with this 59 Mix” at a protein 
concentration of 4 f 1 mg/mL for 60 min at 37’ in giass tubes. The incubation mixture was heat-treated (5~5~ for 
1.5 min) to remove protein without inactivating the metabolite, centrifuged (10,000 g for 10 min), and kept on ice. 
Outer hair cells were isolated from the three upper cochlear turns of pigmented guinea pigs (200-300 g) by 
micr~issection and brief treatment with collagenase (0.5 mg/mL for 10 min). They were m~ntained at room 
temperature in Hanks’ Balanced Salt Solution without bicarbonate, buffered with 5 mM HEPES, pH 7.40, and 
osmolarity adjusted with NaCl to 300 mOsM [12]. To assay cytotoxicity, isolated hair cells were exposed at 
room temperature to a 1: 10 dilution (v/v) of the deproteinated incubation medium in droplets of Hanks’ solution. 
Viability was quantitated based on the exclusion of the nuclear dye propidium iodide, added immediately prior to 
cell counting (final concentration, 4 PM). Stained or enucleated cells were counted as dead. 
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RESULTS 
Metabolism of gentamicin. After incubation with the S9 Mix, metabolized gentamicin significantly 
decreased the viability of cochlear outer hair cells (Figure I and Table I). This was accompanied by mo~hologi~ 
evidence of cell destruction, such as swelling, vacuolization, granularity, loss of birefringence and occasional 
enucleation. In contrast, unmetabolized gentamicin was not cytotoxic under these conditions (Figure I), in 
agreement with our previous data [S]. 
Incubations of the S9 Mix without aminoglycoside antibiotic produced no apparent cytotoxic effect, 
demons~ting the absence of intrinsic toxic substances in the subcell&r fraction (Table I). S9 fraction heat- 
inactivated prior to incubation with gentamicin did not generate a toxic product, suppo~ng an enzymatic basis for 
the formation of cytotoxic metabolite(s). Since commercial gentamicin is a mixture of the structurally related 
gentamicin Cl, Cla and C2 (composition and purity confirmed by TLC analysis [13]) it remains to be established 
whether all or which of the components give rise to a metabolite. Preliminary experiments suggest that 
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Figure I. Time course of cytotoxicity of metabolized gentamicin. The viability of isolated outer hair cells was 
assessed as described in Methods after exposure to: gentamicin-free Hanks’ medium ( 0 ), gentamicin incubated 
with S9 Mix (A ), or gentamicin in a reagent blank without the S9 fraction (V ). Each value is derived from 
observations of at least 100 cells. 
Table I. Requirement for gentamicin and active S9 fraction in the formation of cytotoxic metabolite 
Condition Cells 
(number observed) 
Experiments Viable cells 
(% of total) 
Hanks’ medium 660 20 9026 
S9 Mix + gentamicina 442 14 54+9 
S9 Mix aloneb 218 6 91+7 
Heated S9 + gentamicinC 120 3 85 & 6 
The viabili~ of isolated cochlear outer hair cells was dete~ined as described in Methods after a 75-min 
exposure at room temperature to: {a) gentamicin incubated with S9 Mix; (b) S9 Mix incubated without 
gentamicin; (cl gentamicin incubated with a heat-inactivated S9 fraction ( 100° for 1.5 min) in the Mix. For each 
condition, mean viability + SD was determined from the number of independent experiments and total number of 
cells indicated. Statistical significance of differences: ‘S9 + gentamicin’ differed significantly (P < 0.001; two- 
sample t-test) from each of the other conditions. ‘S9 alone’ and ‘heated S9 + gentamicin’ were not different from 
controls in Hanks’ medium. 
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Inhibition of gentamicin metabolism. Hepatic drug metabolism is frequently associated with cytochrome 
P450 or similar oxygenases. To assess the possible contribution of such enzymes, oxidative reactions were 
suppressed in the incubation (Table II). Two independent approaches were employed: NADP was omitted to 
prevent the generation of NADPH, and ketoconazole was added as a broad-spectrum inhibitor of oxidative 
xenobiotic metabolism [14, 151. Under both conditions, the formation of a toxic product was essentially prevented 
and outer hair cells remained viable. These results strongly suggest a role for mono-oxygenases in the metabolism 
of aminoglycosides. 
Table II. Requirement for oxidative metabolism in the fo~ation of cytotoxic metabolite 
Condition Cells 
(number observed) 
Experiments Viable cells 
(% of total) 
Hanks’ medium 
S9 Mix + gentamicin 
S9 Mix + gentamicin 
but NADP omitted 
S9 Mix + gentamicin 
and ketownazole added 
253 5 88+8 
203 5 5625 
255 5 91+3 
177 5 88~10 
Oxidative metabolism was inhibited by omission of NADP from or addition of 250 pM ketoconazole (in 
0.5% aqueous ethanol, v/v) to the S9 Mix as noted in the table. The viability of isolated outer hair cells was 
assessed as described in Methods after a 75min exposure at room temperature to each condition indicated. Mean 
viability + SD was dete~in~ from the number of independent experiments and total number of cells indicated. 
Statistical significance of differences: ‘S9 f gentamicin’ was significantly different (P : 0.001; two-sample t-test) 
from each of the other conditions. ‘NADP omitted and ‘ketoconazole added were not different from control 
incubations in Hanks’ medium. 
DISCUSSION 
Our data provide the first direct demonstration that metabolism is required for the cytotoxicity of 
aminoglycosides. While several pathways appear compatible with the data at this point, an enzymatic oxidation 
producing one or more cytotoxic metabolites from gentamicin appears the most likely reaction. Regardless of the 
mechanism, the novel and important aspect of these results is the fact that the cytotoxic species is not the parent 
~inoglycoside but a metabolite which is stable for at least several hours following mild heat treatment. 
The existence of a toxic metabolic product may explain why it has been exceedingly difficult to formulate a 
molecular mechanism of aminoglycoside toxicity. For example, the appearance of nephrotoxicity and ototoxicity 
is delayed for days to weeks, despite early peak drug levels in both cochlear and renal tissues 1161. The 
requirement for a toxic metabolite coutd account for the poor correlation between aminoglycoside concentrations 
and the histopathologic damage to either target organ [9, 16-181, and the delay in onset of clinical toxicity could 
represent either the time necessary for induction of the metabolizing enzymes or for the metabolite to reach toxic 
levels. 
The extent of metabolism of aminoglycosides in vivo is unknown. It is conceivable, however, that the 
concentration of the cytotoxic metabolite(s) is relatively low, having thus escaped traditional methods of detection. 
Only the development of outer hair cell isolation [19, 201 and the novel bioassay used here enabled direct 
measurement of cytotoxicity with adequately high sensitivity. 
Further investigation will determine the intracellular location and the inducibility of the metabolizing 
enzyme(s), as well as the chemical structure of the potential metabolite(s). Considering the tissue specificity of 
aminoglycoside toxicity, it needs to be established to what extent this metabolism occurs in extra-hepatic tissues, 
A contribution by local metabolism to the development of organ-specific toxicity is suggested by reports that 
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aminoglycosides applied directly into the fluids of the inner ear [21] or to otocyst organ cultures [22] produce toxic 
effects. 
Past attempts to delineate mechanisms of aminoglycoside toxicity have met with limited success as have 
efforts to design preventative measures. Our findings should lead to new rational approaches to both the 
mechanism and prevention of aminoglycoside-induced toxicity. 
Acknowledeements - This research was supported by NM Grant DC-00124 and Training Grant DC-00024, and 
























Hinsbaw HC and Feldman WH, Streptomycin in treatment of clinical tuberculosis: A preliminary report. 
ProcMuyo Clinic 20: 313-318, 1945. 
Waksman SA, Streptomycin: Background, isolation, properties, and utilization. Science 118: 259-266, 
1953. 
Hawkins JE, Drug ototoxicity. In: Handbook of Sensory Physiology (Eds Keidel WD and Neff WD), pp. 
707-748. Springer, New York, 1976. 
Schacht J, Molecular mechanisms of drug-induced hearing loss. Hearing Res 22: 297-304, 1986. 
Dulon D, Zajic G, Aran J-M and Schacht J, Aminoglycoside antibiotics impair calcium-entry but not 
viability and motility of cochlear outer hair cells. J Neurosci Res 24: 338-346, 1989. 
Hori R, Yamamoto K, Saito H, Kohno M and Inui K, Effect of aminoglycoside antibiotics on cellular 
functions of kidney epithelial cell line (LLC-PKl): A model system for aminoglycoside nephrotoxocity. J 
Pharmacol Exp Ther 230: 742-748, 1984. 
Pierson MG and Moller AR, Prophylaxis of kanamycin-induced ototoxicity by a radioprotectant. Hearing 
Res 4: 79-87, 1981. 
Hoffman DW, Whitworth CA, Jones-King KL and Rybak LP, Potentiation of ototoxicity by glutathione 
depletion. Ann Otol Rhino1 Laryngol 97: 36-41, 1988. 
Sande MA and Mandell GL, In: The Pharmacologicul Basis of Therapeutics (Eds Goodman AG, Gilman 
A, Rall TW and Murad F), 7th Edn, pp. 1150-l 169. Macmillan, New York, 1985. 
Huang M, Dulon D and Schacht J, Outer hair cells as potential targets of inflammatory mediators. Ann 
Otol Rhino1 Luryngol99 (S148): 35-38, 1990. 
Maron DM and Ames BN, In: Handbook of Mutagenicity Test Procedures (Eds Kilbey BJ, Legator M, 
Nichols W and Ramel C), pp. 93-140. Elsevier Science Publishers, Amsterdam, 1984. 
Zajic G and Schacht J, Comparison of isolated outer hair cells from five mammalian species. Hearing Res 
26: 249-256, 1987. 
Sekkat M, Fabre H, Simeon De Buochberg M and Mandrou B, Determination of aminoglycosides in 
pharmaceutical formulations - I. Thin-layer chromatography. J Pharm Biomed Analysis 7: 883-892, 1989. 
Sheets JJ and Mason JI, Ketoconazole: A potent inhibitor of cytochrome P-450-dependent drug 
metabolism in liver. Drug Metab Dispos 12: 603606, 1984. 
Meredith CG, Maldonado AL and Speeg KV, The effect of ketoconazole on hepatic drug metabolism in 
the rat in vivo and in vitro. Drug Metab Dispos 13: 156-162, 1985. 
Tran Ba Huy P, Bernard P and Schacht J, Kinetics of gentamicin uptake and release in the rat: Comparison 
of inner ear tissues and fluids with other organs. J Clin Invest 77: 1492-1500, 1986. 
Koren G, Klein J and MacLeod SM, The dissociation between aminoglycoside serum concentrations and 
nephrotoxicity. Life Sci 43: 1817-1823, 1988. 
Huang MY and Schacht J, Drug-induced ototoxicity: Pathogenesis and prevention. Med Toxic01 Adverse 
Drug Exp 4: 452-467, 1989. 
Brownell WE, Bader CR, Bertrand D and de Ribeaupierre Y, Evoked mechanical responses of isolated 
cochlear hair cells. Science 227: 194-196, 1985. 
Zenner HP, Zimmermann U and Schmitt U, Reversible contraction of isolated mammalian cochlear hair 
cells. Hearing Res 18: 127-133, 1985. 
Takada A and Schacht J, Calcium antagonism and reversibility of gentamicin-induced loss of cochleae 
microphonics in the guinea pig. Hearing Res 8: 179-186, 1982. 
Anniko M, Takada A and Schacht J, Comparative ototoxicities of gentamicin and netilmicin in three model 
systems. Am J Otolaryngol3: 422-433, 1982. 
